LMU Klinikum
LMU Klinikum
München, Germany4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Phase 4 | 2026-09-01 | NCT07788586 | |
| A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-08-05 | NCT05676203 | |
| Targeting Real World Usage In Stroke Treatment | Aneurysm, Aneurysm, False, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Constriction, Pathologic, Infant, Newborn, Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Primary Immunodeficiency Diseases, X-Linked Combined Immunodeficiency Diseases, X-linked disease, brain aneurysm, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, immune system disorder, inborn error of immunity, intracranial arterial disease, nervous system disorder, severe combined immunodeficiency, vascular disorder | Recruiting | Not stated | 2026-03-16 | NCT07474935 | |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 3 | 2026-02-06 | NCT06127407 |